Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Added: 9 months ago Source:  Radcliffe CVRM
A new study has explored the underlying mechanisms by which semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), improves outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH).¹ The research, which combined analysis of a phase 2 clinical trial with preclinical models, identified a unique proteomic signature associated with treatment and suggests that… View more
Author(s): Julia Grapsa , Mirvat Alasnag , Barbara Casadei Added: 1 year ago
What is the reasoning behind the porosity of data when it comes to CV outcomes in women?Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) are joined by Prof Barbara Casadei (British Heart Foundation, University of Oxford, Oxford, UK) who offers her advice… View more
Author(s): Andrew Wang Added: 6 months ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive… View more
Author(s): Ankeet Bhatt Added: 11 months ago
ESC HF 25 - Secondary analysis of the FINEARTS-HF study shows finerenone treatment favourably influenced the risk of early heart failure readmission.Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, San Francisco, US) discusses findings from the prespecified secondary analysis of the FINEARTS-HF trial (NCT04435626; Bayer). The placebo-controlled primary analysis investigated the… View more
Author(s): Rajesh Kharbanda Added: 11 months ago
EuroPCR 25 - A meta-analysis of the individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI studies show TAVI with cerebral embolic protection (CEP) may reduce the rate of disabling stroke compared to TAVI without CEP.We are joined by Prof Rajesh Kharbanda (Oxford Radcliffe Hospitals NHS Trust, Oxford, UK) to discuss outcomes from a meta-analysis investigating TAVI with or without… View more